Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status

被引：33

作者：

Petit, Karina ^{[1
]}

Biard, Jean-Francois ^{[1
]}

机构：

[1] Univ Nantes, LUNAM Univ, MMS, F-44000 Nantes, France

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2013年 / 13卷 / 04期

关键词：

Brentuximab vedotin; Clinical trials; Cytarabine; Elisidepsin; Eribulin; ILX-651; KLH; Marine natural products; MMAE; MMAF; Plinabulin; plitidepsin; PM00104; PM01183; PM060184; Salinosporamide A; Trabectedin; TZT-1027; KEYHOLE-LIMPET HEMOCYANIN; ERIBULIN MESYLATE E7389; HALICHONDRIN B ANALOG; PEGYLATED LIPOSOMAL DOXORUBICIN; SOFT-TISSUE SARCOMA; EVERY; WEEKS; ADJUVANT TOPICAL CHEMOTHERAPY; PROTEASOME INHIBITOR NPI-0052; ACTIVE SPECIFIC IMMUNOTHERAPY; TRANSITIONAL CELL-CARCINOMA;

D O I：

10.2174/1871520611313040010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Marine ecosystems constitute a huge reservoir of biologically active secondary metabolites. Consequently during the last past few decades, several marine-derived molecules have been approved for anticancer treatment or are under clinical trials. This review reports the present state of the art of the sixteen molecules approved or currently on the clinical pipeline for anticancer chemotherapy. The molecules are classified according to their current status in the phase (approved / phase IV / phase III / phase II / phase I) and data are updated to April 2012.

引用

页码：603 / 631

页数：29